At Apexian, our mission is simple:
Find safe and effective therapies that will improve the lives of cancer patients.
Apexian is a biotechnology company focused on developing novel compounds to treat cancer. Our lead drug candidate – APX3330 – targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas and others. Our experienced team of research scientists and clinical specialists will commence studies of APX3330 for the treatment of cancer in 2017.
Our scientific founder and Chief Scientific Officer, Dr. Mark R. Kelley, is the world’s leading expert in APE1/Ref-1 protein biology.
He is also the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor in the Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology, Indiana University School of Medicine. Dr. Kelley is the Associate Director of the Herman B Wells Center for Pediatric Research and for Basic Science Research at the IU Simon Cancer Center.
Our science is unique and represents first-in-class therapeutic potential.
Inhibition of the APE1/Ref-1 redox protein affects signaling pathways critical to cancer cell survival, and APX3330 has shown dramatic anti-cancer effect in numerous pre-clinical models of human cancers. Our human studies will evaluate the safety and efficacy of APX3330 in patients with a variety of cancers that express the APE1/Ref-1 protein.
Our focus is on developing drugs to fight the most deadly cancers, most of which overexpress APE1
Our clinical development plan is focused on testing APX3330 against advanced cancers that express the APE1/Ref-1 protein. These advanced cancers constitute areas of high unmet medical need, and include deadly forms of cancer involving the lung, colon, breast, pancreas, brain and others. The APE1/Ref-1 protein is also expressed in certain pediatric and hematologic cancers, underscoring the importance of this molecular target.
LATEST APEXIAN NEWS
NIH Awards Grant for Research on APX3330 as Treatment for Cancer Cachexia
National Cancer Institute Funding Brings Research Grant Budget to Nearly $700,000
INDIANAPOLIS, Ind. – Researchers will continue to explore the impact of Apexian’s target molecule, APX3330, on cancer cachexia with additional grant funding from the National Institutes of Health (NIH) National Cancer Institute (NCI). Cancer cachexia is weight loss with chronic inflammation and defective metabolism, which causes roughly one-third of all cancer deaths. It is particularly prevalent in pancreatic ductal adenocarcinoma (PDAC), which has a dismal five-year survival rate.
+ Read this story
+ Read all Apexian News